
ICON8 trials programme
N=1485
ICON8
ICON8B
N=1170
Stage IC-IV EOC/PPC/FTC
Randomise 1:1:1
Arm 1 6 cycles
Arm 2 6 cycles
Arm 3 6 cycles
Arm 1 Carboplatin AUC 5 q3w Paclitaxel 175mg/m² q3w
Arm 2 Carboplatin AUC 5 q3w Paclitaxel 80mg/m² q1w
Arm 3 Carboplatin AUC 2 q1w Paclitaxel 80mg/m² q1w
NB. High-risk patients remain eligible for ICON8 so that patients with contra-indications to bevacizumab and those unable to access it are still able to enter the trial
High-risk* stage III -IV EOC/PPC/FTC
Randomise 1:1:1
Arm B1 6 cycles
Arm B2 6 cycles
Arm B3 6 cycles
Maintenance bevacizumab (18 Cycle Total)
6-weekly follow-up until week 66 post randomisation
Maintenance bevacizumab (18 Cycle Total)
Arm B1 Carboplatin AUC 5 q3w Paclitaxel 175mg/m² q3w Bevacizumab 7.5 mg/kg q3w
Arm B2 Carboplatin AUC 5 q3w Paclitaxel 80mg/m² q1w
Arm B3 Carboplatin AUC 5 q3w Paclitaxel 80mg/m² q1w Bevacizumab 7.5 mg/kg q3w
High-risk defined as (1) FIGO (2013) stage IIIA1(ii), IIIA2 with positive retroperitoneal lymph nodes >1cm in diameter, stage IIIB or IIIC with >1cm residual disease following immediate primary surgery or planned to receive primary chemotherapy +/- delayed primary surgery and (2) FIGO (2013) stage IV

- Accrual began 06/06/2011 and ICON8 pathway closed to recruitment 28/11/2014



- Final recruitment figure = **1566**
- UK= 1397, ANZGOG= 70, GICOM= 43, KGOG= 32, ICORG= 24

ICON8 Outcome measures & analysis

Presentations:
ESMO, October 2016 - poster on stage IA and IB analysis

- **Stage 1A** showed that the weekly regimens were harder to deliver but total doses and dose intensity were increased. Uncomplicated grade 3/4 neutropenia was higher in Arms 2&3 but other toxicities were similar. Earlier use of GCSF was recommended following this analysis.

- **Stage 1B** was reviewed by the IDMC in Nov-13. They considered the regimens safe and feasible for neo-adjuvant chemotherapy. DPS was not compromised in the weekly arms.

- **Stage 2** Activity Outcome measure: 9-month progression free survival rate in 1st 186 women randomised Completed Jan-14. Analysis reviewed by Independent Data Monitoring Committee, decision to continue all arms

- **Primary Progression Free survival analysis:** Completed April 2017, submitted to ESMO 2017 for presentation

ICON8B

A study of bevacizumab and weekly dose-dense paclitaxel in ovarian cancer

Following the ICON8 PFS analysis, recruitment to Arm B2 has been suspended whilst a protocol amendment is prepared. Trial to continue as 2-arm study (B1 vs B3). Provisional amended recruitment target – 700.
Modified comparator arms as of May 2017:

Arm B1	Carboplatin AUC 5	q3w
	Paclitaxel 175mg/m^2	q3w
	Bevacizumab 7.5mg/kg	q3w

Arm B3	Carboplatin AUC 5	q3w
	Paclitaxel 80mg/m^2	q1w
	Bevacizumab 7.5mg/kg	q3w

Will be an international trial with participation interest from Switzerland and Mexico

ICON8B Trial Progress

ICON8B submitted as an amendment to the ICON8 trial in January 2015

Overarching trial title changed to the ICON8 Trials Programme encompassing ICON8 and ICON8B

Full UK ethical and MHRA approval gained by February 2015

First site opened to recruitment 21st July 2015

83 sites open to recruitment as of May 2017



First patient recruited 24th July 2015

Accrual data up until 9th May 2017

Accrual total to date: 385